Treatment with dimethyl fumarate corresponds with the needs of patients with relapsing-remitting multiple sclerosis – case report Case report
Article Sidebar
Published:
Mar 31, 2024
Keywords:
multiple sclerosis, relapsing-remitting, disease-modifying therapy, dimethyl fumarate, pregnancy
Main Article Content
Abstract
Personalization of disease-modifying treatment, currently recommended for patients with multiple sclerosis, is based on the analysis of effectiveness and safety as well as the patient’s individual preferences for therapy. In the described patient with an active, relapsing-remitting form of multiple sclerosis, treatment with dimethyl fumarate caused a long-term clinical and radiological stabilization of the disease, was well tolerated by the patient and enabled her successful pregnancy planning.
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2): 292-302.
2. Kułakowska A, Mirowska-Guzel D, Alicja Kalinowska A et al. Leczenie modyfikujące przebieg stwardnienia rozsianego. Rekomendacje Sekcji Stwardnienia Rozsianego i Neuroimmunologii Polskiego Towarzystwa Neurologicznego. Pol Przegl Neurol. 2023; 19(3): 163-89.
3. Giovannoni G, Turner B, Gnanapavan S et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015; 4(4): 329-33.
4. Gold R, Arnold DL, Bar-Or A et al. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Mult Scler. 2022; 28(5): 801-16.
5. Pandey K, Giles K, Balashov K et al. Long-Term Safety and Effectiveness of Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice, an updated analysis of the ESTEEM Study (P7-3.009). Neurology. 2023; 100(17 suppl 2): 1518.
6. Bosco-Lévy P, Debouverie M, Brochet B et al. Comparative effectiveness of dimethyl fumarate in multiple sclerosis. Br J Clin Pharmacol. 2022; 88(3): 1268-78.
7. Hillert J, Tsai JA, Nouhi M et al. A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry. Mult Scler. 2022; 28(2): 237-46.
8. Hellwig K, Rog D, McGuigan C et al. Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry. Neurol Neuroimmunol Neuroinflamm. 2021; 23; 9(1): e1114.
9. Amato MP. Getting Evidence into practice: The new EAN-ECTRIMS guideline “Update on the pharmacological treatment of people with multiple sclerosis”. SYMP02, EAN 2022, 25–28 April, Vienna, Austria.
10. ChPL Tecfidera 10.2023.
2. Kułakowska A, Mirowska-Guzel D, Alicja Kalinowska A et al. Leczenie modyfikujące przebieg stwardnienia rozsianego. Rekomendacje Sekcji Stwardnienia Rozsianego i Neuroimmunologii Polskiego Towarzystwa Neurologicznego. Pol Przegl Neurol. 2023; 19(3): 163-89.
3. Giovannoni G, Turner B, Gnanapavan S et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015; 4(4): 329-33.
4. Gold R, Arnold DL, Bar-Or A et al. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Mult Scler. 2022; 28(5): 801-16.
5. Pandey K, Giles K, Balashov K et al. Long-Term Safety and Effectiveness of Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice, an updated analysis of the ESTEEM Study (P7-3.009). Neurology. 2023; 100(17 suppl 2): 1518.
6. Bosco-Lévy P, Debouverie M, Brochet B et al. Comparative effectiveness of dimethyl fumarate in multiple sclerosis. Br J Clin Pharmacol. 2022; 88(3): 1268-78.
7. Hillert J, Tsai JA, Nouhi M et al. A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry. Mult Scler. 2022; 28(2): 237-46.
8. Hellwig K, Rog D, McGuigan C et al. Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry. Neurol Neuroimmunol Neuroinflamm. 2021; 23; 9(1): e1114.
9. Amato MP. Getting Evidence into practice: The new EAN-ECTRIMS guideline “Update on the pharmacological treatment of people with multiple sclerosis”. SYMP02, EAN 2022, 25–28 April, Vienna, Austria.
10. ChPL Tecfidera 10.2023.